![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 30, 2018 9:43:48 AM
Japan is an expensive market to enter. Japan did not, "through it back at them and asked them to leave their country". The party with the distribution rights for Japan did not have the financial resources to enter the market.
It cost $10k for a 2 hour meeting with the PMDA regulatory agency in Japan and $107k to register a medical device. This is after you have paid tens of thousands of dollars to a DMAH/MAH, an in country representative for your product. You also still need the services a distributor.
ActiPatch successfully entered the Medical Device Markets of the United Kingdom, Australia, Germany, Sweden, Italy, Spain and a dozen other countries.
The "flimsy POS" is solely the opinion of an anonymous message board poster not Japan or the US FDA who has Cleared the ActiPatch for 3 Indications.
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM